PMID- 28905639
OWN - NLM
STAT- MEDLINE
DCOM- 20190820
LR  - 20190820
IS  - 1938-2707 (Electronic)
IS  - 0009-9228 (Linking)
VI  - 57
IP  - 4
DP  - 2018 Apr
TI  - Clinical Manifestations of Kawasaki Disease Shock Syndrome.
PG  - 428-435
LID - 10.1177/0009922817729483 [doi]
AB  - A case-control study was performed to ascertain clinical features of children who 
      had been diagnosed as Kawasaki disease shock syndrome (KDSS), a severe condition 
      related to Kawasaki disease (KD). Hospitalized patients were selected in Nanjing 
      Children's Hospital. Demographic characteristics, clinical presentation, 
      laboratory data, cardiovascular findings, and therapies were analyzed. Compared 
      with the control group, KDSS patients were older and had more serious skin rash. 
      The proportions of leukocytosis, neutrophilia, and hypoalbuminemia was higher, as 
      was the level of while blood cell count, C-reactive protein, brain natriuretic 
      peptide, and ferroprotein. KDSS patients had higher incidence of arrhythmias and 
      more severe coronary artery involvement. All case patients received aspirin, 
      glucocorticoid, and intravenous immunoglobulin, 33.3% required albumin, and 90.4% 
      needed vasoactive infusions. In conclusion, KDSS patients may have more serious 
      inflammatory responses in the acute phase. Short-term use of glucocorticoid may 
      be important in inhibiting the inflammatory response. Albumin and vasoactive 
      drugs are useful to rescue shock.
FAU - Ma, Le
AU  - Ma L
AD  - 1 Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, 
      China.
FAU - Zhang, Ya-Yuan
AU  - Zhang YY
AD  - 1 Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, 
      China.
FAU - Yu, Hai-Guo
AU  - Yu HG
AD  - 1 Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170914
PL  - United States
TA  - Clin Pediatr (Phila)
JT  - Clinical pediatrics
JID - 0372606
RN  - 0 (Albumins)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - R16CO5Y76E (Aspirin)
MH  - Adolescent
MH  - Albumins/therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*complications/drug therapy/*physiopathology
MH  - Shock/*complications/drug therapy/*physiopathology
MH  - Syndrome
OTO - NOTNLM
OT  - Kawasaki disease
OT  - Kawasaki disease shock syndrome
EDAT- 2017/09/15 06:00
MHDA- 2019/08/21 06:00
CRDT- 2017/09/15 06:00
PHST- 2017/09/15 06:00 [pubmed]
PHST- 2019/08/21 06:00 [medline]
PHST- 2017/09/15 06:00 [entrez]
AID - 10.1177/0009922817729483 [doi]
PST - ppublish
SO  - Clin Pediatr (Phila). 2018 Apr;57(4):428-435. doi: 10.1177/0009922817729483. Epub 
      2017 Sep 14.